<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: may differ materially from", fill: "#915f6d"},
{source: "2: may differ materially from", target: "2: forwardlooking", fill: "#915f6d"},
{source: "2: forwardlooking", target: "2: important factors", fill: "#915f6d"},
{source: "2: important factors", target: "2: could affect", fill: "#915f6d"},
{source: "2: could affect", target: "2: actual future", fill: "#915f6d"},
{source: "2: actual future", target: "2: product development programs contract", fill: "#915f6d"},
{source: "2: product development programs contract", target: "2: revenues expenses net loss", fill: "#915f6d"},
{source: "2: revenues expenses net loss", target: "2: earnings per", fill: "#915f6d"},
{source: "2: may differ materially from", target: "11: spend significant amounts", fill: "#00ffef"},
{source: "11: spend significant amounts", target: "11: fund research", fill: "#00ffef"},
{source: "11: fund research", target: "11: development", fill: "#00ffef"},
{source: "11: development", target: "11: core technologies", fill: "#00ffef"},
{source: "11: spend significant amounts", target: "12: manufacture", fill: "#da2c43"},
{source: "12: manufacture", target: "12: candidates", fill: "#da2c43"},
{source: "12: manufacture", target: "18: conduct research", fill: "#997a8d"},
{source: "18: conduct research", target: "18: activities prior", fill: "#997a8d"},
{source: "18: activities prior", target: "18: commercialization", fill: "#997a8d"},
{source: "18: commercialization", target: "18: potential products", fill: "#997a8d"},
{source: "18: conduct research", target: "19: such funds will", fill: "#dda0dd"},
{source: "19: such funds will", target: "19: from external sources", fill: "#dda0dd"},
{source: "19: from external sources", target: "19: additional", fill: "#dda0dd"},
{source: "19: additional", target: "19: equity debt", fill: "#dda0dd"},
{source: "19: equity debt", target: "19: lease financing", fill: "#dda0dd"},
{source: "19: lease financing", target: "19: collaborative", fill: "#dda0dd"},
{source: "19: collaborative", target: "19: agreements with corporate governmental", fill: "#dda0dd"},
{source: "19: agreements with corporate governmental", target: "19: academic collaborators", fill: "#dda0dd"},
{source: "19: academic collaborators", target: "19: future operations", fill: "#dda0dd"},
{source: "19: such funds will", target: "25: additional funds on", fill: "#915f6d"},
{source: "25: additional funds on", target: "25: preclinical studies", fill: "#915f6d"},
{source: "25: preclinical studies", target: "25: clinical trials", fill: "#915f6d"},
{source: "25: clinical trials", target: "25: candidates from", fill: "#915f6d"},
{source: "25: candidates from", target: "25: regulatory authorities", fill: "#915f6d"},
{source: "25: additional funds on", target: "28: find collaborators", fill: "#66424d"},
{source: "28: find collaborators", target: "28: commercialize", fill: "#66424d"},
{source: "28: find collaborators", target: "30: strategy depends", fill: "#edc9af"},
{source: "30: strategy depends", target: "30: enter into", fill: "#edc9af"},
{source: "30: enter into", target: "30: collaborations", fill: "#edc9af"},
{source: "30: collaborations", target: "30: development", fill: "#edc9af"},
{source: "30: development", target: "30: commercialization", fill: "#edc9af"},
{source: "30: commercialization", target: "30: product candidates", fill: "#edc9af"},
{source: "30: strategy depends", target: "41: collaborators will", fill: "#b0e0e6"},
{source: "41: collaborators will", target: "41: collaborations might", fill: "#b0e0e6"},
{source: "41: collaborations might", target: "41: could delay", fill: "#b0e0e6"},
{source: "41: could delay", target: "41: development", fill: "#b0e0e6"},
{source: "41: development", target: "41: commercialization", fill: "#b0e0e6"},
{source: "41: commercialization", target: "41: potential product candidates", fill: "#b0e0e6"},
{source: "41: potential product candidates", target: "41: negatively impact", fill: "#b0e0e6"},
{source: "41: negatively impact", target: "41: financial condition", fill: "#b0e0e6"},
{source: "41: collaborators will", target: "45: collaborators", fill: "#0077be"},
{source: "45: collaborators", target: "45: collaborative", fill: "#0077be"},
{source: "45: collaborative", target: "45: arrangements", fill: "#0077be"},
{source: "45: arrangements", target: "45: devote sufficient resources", fill: "#0077be"},
{source: "45: devote sufficient resources", target: "45: development regulatory approval manufacture marketing", fill: "#0077be"},
{source: "45: collaborators", target: "46: technologies", fill: "#ff1dce"},
{source: "46: technologies", target: "46: commercialize", fill: "#ff1dce"},
{source: "46: technologies", target: "START_HERE", fill: "#ff1dce"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Fertilizers and Agricultural Chemicals</td>
    </tr>
    <tr>
      <td>Diversified Chemicals</td>
    </tr>
    <tr>
      <td>Specialty Chemicals</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_development">Human development</a></td>
      <td>The Human Development Index (HDI) is a statistic composite index of life expectancy, education (mean years of schooling completed and expected years of schooling upon entering the education system), and per capita income indicators, which are used to rank countries into four tiers of human development. A country scores a higher level of HDI when the lifespan is higher, the education level is higher, and the gross national income GNI (PPP) per capita is higher.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of which 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Officer_candidate">Officer candidate</a></td>
      <td>Officer candidate or officer aspirant (OA) is a rank in some militaries of the world that is an appointed position while a person is in training to become an officer.  More often than not, an officer candidate was a civilian who applied to join the military directly as an officer.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioprospecting">Bioprospecting</a></td>
      <td>Bioprospecting (also known as biodiversity prospecting) is the exploration of natural sources for small molecules, macromolecules and biochemical and genetic information that could be developed into commercially valuable products for the agricultural, aquaculture, bioremediation, cosmetics, nanotechnology, or pharmaceutical industries. In the pharmaceutical industry, for example,  almost one third of all small-molecule drugs approved by the U.S. Food and Drug Administration (FDA) between 1981 and 2014 were either natural products or compounds derived from natural products.Terrestrial plants, fungi and actinobacteria have been the focus of many past bioprospecting programs, but interest is growing in less explored ecosystems (e.g.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborators_(Battlestar_Galactica)">Collaborators (Battlestar Galactica)</a></td>
      <td>"Collaborators"  is the fifth episode of the third season from the science fiction television series Battlestar Galactica.\nThis is the first episode of season 3 to include a survivor count, at 41,435, down considerably from the 49,550 shown in "Lay Down Your Burdens" (Part 2).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_engineering">Collaborative engineering</a></td>
      <td>Collaborative engineering is defined by the International Journal of Collaborative Engineering as a discipline that "studies the interactive process of engineering collaboration, whereby multiple interested stakeholders resolve conflicts, bargain for individual or collective advantages, agree upon courses of action, and/or attempt to craft joint outcomes which serve their mutual interests."Collaborative engineering is quickly becoming a topic of great interest in recent years due to the explosion of internet technologies. This upsurge is partially due to the success of projects such as Wikipedia and Linux that have proven the efficacy of internet collaboration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Raytheon_Technologies">Raytheon Technologies</a></td>
      <td>Raytheon Technologies Corporation is an American multinational aerospace and defense conglomerate headquartered in Waltham, Massachusetts. It is one of the largest aerospace, intelligence services providers, and defense manufacturers in the world by revenue and market capitalization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/HCL_Technologies">HCL Technologies</a></td>
      <td>HCL Technologies (Hindustan Computers Limited) is an Indian multinational information technology (IT) services and consulting company headquartered in Noida. It is a subsidiary of HCL Enterprise.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GENVEC INC      ITEM 1A RISK FACTORS     This Form 10-K contains forward-looking information <font color="blue">based on</font> our current     <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>Because our actual results <font color="blue">may differ materially from</font> any     forward-looking  statements  made  by  GenVec, this section includes a     discussion of <font color="blue">important factors</font> that <font color="blue">could affect</font> our <font color="blue">actual future</font> results,     including, but not limited to, our product <font color="blue">development</font> programs, contract     revenues, expenses, net loss and <font color="blue">earnings per</font> share</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR BUSINESS     We have a history of losses and anticipate <font color="blue">future losses</font></td>
    </tr>
    <tr>
      <td>We  have  incurred  net  losses  in  each  year since our inception in     <font color="blue">December </font>1992, including a net loss of dlra14dtta0 million for the year ended     <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had an <font color="blue">accumulated deficit</font> of     <font color="blue">approximately</font>  dlra150dtta0 million</td>
    </tr>
    <tr>
      <td>The size of our <font color="blue">net losses will depend</font>, in part, on the growth     rate of our revenues and the level of our expenses</td>
    </tr>
    <tr>
      <td>We  derive  <font color="blue">substantially</font>  all  of  our  revenues  from  <font color="blue">payments from</font>     <font color="blue"><font color="blue">collaborations</font> with corporations</font> and <font color="blue"><font color="blue">government</font> entities</font>, and <font color="blue">will continue</font>     to do so for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We expect that it will be several     years, if ever, before we will recognize <font color="blue">revenue from product candidate</font>     sales or royalties</td>
    </tr>
    <tr>
      <td>A large portion of our expenses is fixed, including     expenses related to <font color="blue">facilities</font>, equipment and personnel</td>
    </tr>
    <tr>
      <td>In addition, we     expect to <font color="blue">spend <font color="blue">significant</font> amounts</font> to <font color="blue">fund research</font> and <font color="blue">development</font> and to     enhance our <font color="blue">core <font color="blue">technologies</font></font></td>
    </tr>
    <tr>
      <td>We also expect to incur substantial costs to     <font color="blue">manufacture</font>  our  product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>As a result, we expect that our     operating expenses will increase <font color="blue">significant</font>ly over the next several years     and, <font color="blue">consequently</font>, we will need to generate <font color="blue">significant</font> <font color="blue">additional</font> revenue     to achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we may not be     able to sustain or increase <font color="blue">profitability</font> on a <font color="blue">consistent basis</font></td>
    </tr>
    <tr>
      <td>14       _________________________________________________________________           We will have <font color="blue">no product revenues</font> in the near term and may need to raise     <font color="blue">additional</font> capital to operate our business</td>
    </tr>
    <tr>
      <td>We  are focused on clinical product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Until, and unless, we     receive approval from the FDA and other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font> for our     product <font color="blue">candidates</font>, we <font color="blue">cannot sell</font> these products and will not have product     revenues</td>
    </tr>
    <tr>
      <td>We  will  require substantial funds to <font color="blue">conduct research</font> and     <font color="blue">development</font> <font color="blue">activities</font>, <font color="blue">preclinical studies</font>, <font color="blue">clinical trials</font> and other     <font color="blue"><font color="blue">activities</font> prior</font> to the <font color="blue">commercialization</font> of any <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We     anticipate that <font color="blue">such funds will</font> be obtained <font color="blue">from external sources</font> and intend     to  seek  <font color="blue">additional</font>  equity, debt or <font color="blue">lease financing</font> or <font color="blue">collaborative</font>     <font color="blue">agreements</font> with corporate, <font color="blue">government</font>al or <font color="blue">academic <font color="blue">collaborators</font></font> to fund     <font color="blue">future <font color="blue">operations</font></font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">actual capital <font color="blue">requirements</font> will depend on</font> many     factors</td>
    </tr>
    <tr>
      <td>If we experience <font color="blue">unanticipated cash <font color="blue">requirements</font></font>, we may need to     seek <font color="blue">additional</font> sources of funding, which may not be <font color="blue">available on</font> favorable     terms, if at all</td>
    </tr>
    <tr>
      <td>Such <font color="blue">additional</font> funding may only be <font color="blue">available on</font> terms     that may cause dilution to <font color="blue">common stockholders</font>, have <font color="blue">liquidation preferences</font>     and/or pre-emptive rights</td>
    </tr>
    <tr>
      <td>For example, pursuant to an Investor     Rights  Agreement between GenVec and HealthCare Ventures V, LP dated     <font color="blue">December </font>21, 2001, <font color="blue">HealthCare Ventures V and VI </font>have the right to purchase     shares of GenVec common that we <font color="blue">may propose</font> to sell in the future to prevent     dilution of their interest in the company</td>
    </tr>
    <tr>
      <td>If we do not succeed in raising     <font color="blue">additional</font> funds on acceptable terms, we may be unable to complete planned     <font color="blue">preclinical studies</font> and <font color="blue">clinical trials</font> or obtain approval of our product     <font color="blue">candidates</font> from the FDA and other <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>In addition, we     could be forced to <font color="blue">discontinue</font> product <font color="blue">development</font>, reduce or <font color="blue">forego sales</font>     and <font color="blue">marketing efforts</font> and attractive business <font color="blue">opportunities</font> or <font color="blue">discontinue</font>     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to develop, obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of and <font color="blue">commercialize</font> our     <font color="blue">potential products</font> depends, in part, <font color="blue">on <font color="blue">collaborations</font> with</font> other companies</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">find <font color="blue">collaborators</font></font>, we may not be able to develop, test     and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>To date, we only have entered into <font color="blue">collaborative</font> <font color="blue">agreements</font> with a limited     number of companies, and some of those are no longer in effect</td>
    </tr>
    <tr>
      <td>The success     of our business <font color="blue">strategy depends</font>, in part, on our ability to <font color="blue">enter into</font> and     sustain  <font color="blue">collaborations</font>  with  other companies for the <font color="blue">development</font> and     <font color="blue">commercialization</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Unless we are able to enter     into and <font color="blue">sustain collaboration <font color="blue">agreements</font></font>, we will need to raise <font color="blue">additional</font>     funds for the <font color="blue">development</font>, testing, and <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">collaborations</font> or other funding is not available, we may have     to delay or curtail the <font color="blue">development</font> and <font color="blue">commercialization</font> of <font color="blue">certain product</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have experienced, and <font color="blue">may continue</font> to experience, delays in conducting     our <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Clinical trials for the product <font color="blue">candidates</font> we are developing may be delayed     by many factors, including that <font color="blue">potential <font color="blue">appropriate</font> patients</font> for studies     are limited in number and may be <font color="blue">difficult</font> to recruit</td>
    </tr>
    <tr>
      <td><font color="blue">Following </font>the release     of  our  TNFerade  <font color="blue">clinical trails from clinical</font> hold in 2005, we have     experienced delays in <font color="blue">enrolling patients into</font> our TNFerade <font color="blue">clinical trials</font>     and may have <font color="blue">additional</font> delays as we seek to <font color="blue">expand enrollment</font></td>
    </tr>
    <tr>
      <td>Our ability     to <font color="blue">enroll <font color="blue">appropriate</font> patients</font> for any of our <font color="blue">clinical trials</font> also may be     <font color="blue"><font color="blue">adversely</font> affected by trials</font> being <font color="blue">conducted by</font> our <font color="blue"><font color="blue">competitor</font>s</font> for similar     <font color="blue">disease <font color="blue">indications</font></font></td>
    </tr>
    <tr>
      <td>The failure of any <font color="blue">clinical trials</font> to <font color="blue">meet applicable</font>     <font color="blue"><font color="blue">regulatory</font> standards</font> or the standards of the <font color="blue">relevant reviewing bodies could</font>     cause such trials to be delayed or terminated, which could further delay the     <font color="blue">development</font> of any of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue"><font color="blue">such delays</font> increase</font> our     product <font color="blue">development</font> costs, with the <font color="blue">possibility</font> that we <font color="blue">could run out</font> of     funding</td>
    </tr>
    <tr>
      <td>Delays in one clinical trial also can <font color="blue">adversely</font> affect our ability     to  launch  clinical  trials  for  similar  or  <font color="blue">different</font> <font color="blue">indications</font></td>
    </tr>
    <tr>
      <td>Consequently, if <font color="blue">such delays</font> are <font color="blue">significant</font> they <font color="blue"><font color="blue">could <font color="blue">negatively</font></font> affect</font>     our financial results and the <font color="blue">commercial prospects</font> for our products</td>
    </tr>
    <tr>
      <td>We cannot be sure that our <font color="blue"><font color="blue">collaborators</font> will</font> perform as expected, and     <font color="blue">collaborations</font> might produce conflicts that <font color="blue">could delay</font> or prevent the     <font color="blue">development</font> or <font color="blue">commercialization</font> of our potential product <font color="blue">candidates</font> and     <font color="blue"><font color="blue">negatively</font> impact</font> our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot control</font> the resources that any <font color="blue">collaborator may devote</font> to our     products</td>
    </tr>
    <tr>
      <td>Our  present  or <font color="blue">future <font color="blue">collaborators</font> may</font> not perform their     <font color="blue">obligations as</font> expected</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">collaborators</font> may breach</font> or terminate their     <font color="blue">agreements</font>  with  us  or <font color="blue">otherwise fail</font> to conduct their <font color="blue">collaborative</font>     <font color="blue">activities</font>  <font color="blue">successfully</font>  and  in  a  timely  manner</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue">collaborators</font>  may  elect  not  to develop products arising out of our     <font color="blue">collaborative</font>  <font color="blue">arrangements</font>  or  to <font color="blue">devote sufficient resources</font> to the     <font color="blue">development</font>, <font color="blue"><font color="blue">regulatory</font> approval</font>, <font color="blue">manufacture</font>, marketing or sale of these     products</td>
    </tr>
    <tr>
      <td>If any of these events occur, we may not be able to develop our     <font color="blue">technologies</font> or <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________           An important part of our <font color="blue">strategy involves conducting multiple product</font>     <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We may pursue <font color="blue">opportunities</font> in fields that conflict     with  those  of our <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>In addition, dis<font color="blue">agreements</font> with our     <font color="blue">collaborators</font> could develop <font color="blue">over rights</font> to our <font color="blue"><font color="blue">intellectual</font> property</font></td>
    </tr>
    <tr>
      <td>The     resolution of <font color="blue">such conflicts</font> and dis<font color="blue">agreements</font> may require us to <font color="blue">relinquish</font>     rights to our <font color="blue"><font color="blue">intellectual</font> property</font> that we believe we are entitled to</td>
    </tr>
    <tr>
      <td>In     addition, any <font color="blue">disagreement</font> or <font color="blue">conflict with</font> our <font color="blue">collaborators</font> could reduce     our ability to obtain future collaboration <font color="blue">agreements</font> and <font color="blue"><font color="blue">negatively</font> impact</font>     our  <font color="blue">relationship</font>  with  existing  <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>Such  a conflict or     <font color="blue">disagreement</font>  could  also  lead  to  delays in <font color="blue">collaborative</font> research,     <font color="blue">development</font>, <font color="blue"><font color="blue">regulatory</font> approval</font> or <font color="blue">commercialization</font> of various products or     could require or result in <font color="blue">litigation</font> or <font color="blue">arbitration</font>, which would be time     consuming and expensive and could have a <font color="blue">significant</font> negative impact on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our collaboration <font color="blue">agreements</font> may prohibit us from conducting research in     areas  that  may  compete  with  our collaboration products, while our     <font color="blue">collaborators</font> may not be limited to the <font color="blue">same extent</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could <font color="blue">negatively</font></font>     affect our ability to develop products and, ultimately, prevent us from     achieving a <font color="blue">continuing source</font> of revenues</td>
    </tr>
    <tr>
      <td>We anticipate that some of our corporate or <font color="blue">academic <font color="blue">collaborators</font></font> will be     conducting multiple product <font color="blue">development</font> efforts within each disease area     that is the subject of its <font color="blue"><font color="blue">collaboration with</font> us</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">generally</font> have agreed     not to <font color="blue">conduct in<font color="blue">dependent</font>ly</font>, or with any third party, certain research that     is  <font color="blue">competitive</font>  with the <font color="blue">research conducted under</font> our <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>Therefore, our <font color="blue">collaborations</font> may have the effect of limiting the areas of     research  that we may pursue, either alone or <font color="blue">with others</font></td>
    </tr>
    <tr>
      <td>Some of our     <font color="blue">collaborators</font>, however, may develop, either alone or <font color="blue">with others</font>, products     in  related fields that are <font color="blue">competitive</font> with the products or potential     products that are the subject of their <font color="blue">collaborations</font> with us</td>
    </tr>
    <tr>
      <td>In addition,     competing products, either developed by the <font color="blue">collaborators</font> or to which the     <font color="blue">collaborators</font> have rights, may result in their <font color="blue">withdrawing support</font> for our     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">Generally  </font>under  our  academic <font color="blue">collaborations</font>, we retain the right to     <font color="blue">exclusively license</font> any <font color="blue">technologies</font> developed <font color="blue">using funding</font> we provided</td>
    </tr>
    <tr>
      <td>If     we elect to not license a <font color="blue">particular <font color="blue">technology</font></font>, the <font color="blue">academic collaborator</font>     is <font color="blue">typically free</font> to use the <font color="blue">technology</font> for any purpose, including the     <font color="blue">development</font> and <font color="blue">commercialization</font> of products that <font color="blue">might <font color="blue">compete with</font></font> our     products</td>
    </tr>
    <tr>
      <td>We are an early stage company deploying unproven <font color="blue">technologies</font>, and we may     never be able to develop, get <font color="blue"><font color="blue">regulatory</font> approval</font> of, or market any of our     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Gene-based products are new and rapidly evolving medical approaches, which     have not been shown to be <font color="blue"><font color="blue">effective</font> on</font> a <font color="blue">widespread basis</font></td>
    </tr>
    <tr>
      <td>Bio<font color="blue">technology</font> and     <font color="blue">pharmaceutical</font> companies have <font color="blue">successfully</font> developed and <font color="blue">commercialize</font>d only     a  limited number of gene-based products to date</td>
    </tr>
    <tr>
      <td>In addition, no gene     therapy product has received <font color="blue"><font color="blue">regulatory</font> approval</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>To     date, none of our product <font color="blue">candidates</font> has <font color="blue">been approved</font> for sale in the     <font color="blue">United States</font> or elsewhere</td>
    </tr>
    <tr>
      <td>We may be unable to develop products or delivery     systems that:       •   prove to be safe and <font color="blue">effective</font>;         •   <font color="blue">meet applicable</font> <font color="blue"><font color="blue">regulatory</font> standards</font>;         •   are capable of being <font color="blue">manufacture</font>d at reasonable costs;         •   do not infringe the <font color="blue"><font color="blue">intellectual</font> property</font> rights of <font color="blue">third parties</font>;         •   are superior to products offered by <font color="blue">third parties</font>; or         •   can be marketed <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>Gene-based  products  may  be  susceptible to <font color="blue">various risks</font>, including     undesirable and unintended side <font color="blue">effects from genes</font> or the <font color="blue">delivery systems</font>,     unintended  <font color="blue">immune responses</font>, inadequate <font color="blue">therapeutic efficacy</font> or other     <font color="blue">characteristics</font> that <font color="blue">may prevent</font> or limit their approval or <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td><font color="blue">Successful  </font>products  require  <font color="blue">significant</font> <font color="blue">development</font> and <font color="blue">investment</font>,     including a lengthy and <font color="blue">uncertain period</font> of testing to show their safety and     <font color="blue">effective</font>ness before their <font color="blue"><font color="blue">regulatory</font> approval</font> or <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>We have     not  proven  our  ability to develop, obtain <font color="blue"><font color="blue">regulatory</font> approval</font> of or     <font color="blue">commercialize</font> gene-based medicines or <font color="blue">cell transplantation products</font></td>
    </tr>
    <tr>
      <td>We may     be  unable  to  <font color="blue">successfully</font> select those genes or <font color="blue">cells with</font> the most     potential for commercial <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________           If  we  fail to <font color="blue">adequately show</font> the safety and efficacy of our product     <font color="blue">candidates</font>,  we will not be able to obtain FDA approval of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We face the risk of <font color="blue">failure involved</font> in developing therapies <font color="blue">based on</font> new     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>While certain of our product <font color="blue">candidates</font> are in clinical     trials,  there are others for which we have not <font color="blue">yet initiated clinical</font>     trials</td>
    </tr>
    <tr>
      <td>For those product <font color="blue">candidates</font> not yet in <font color="blue">clinical trials</font>, we will     need to conduct <font color="blue">significant</font> <font color="blue">additional</font> research and animal testing, referred     to  <font color="blue">as pre<font color="blue">clinical testing</font></font>, before any of these product <font color="blue">candidates</font> can     advance to <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In addition, we will need to <font color="blue">conduct further</font>     <font color="blue">clinical testing</font> of those product <font color="blue">candidates</font> currently in <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>It may take us many years to complete pre<font color="blue">clinical testing</font> or trials, and     <font color="blue">failure could</font> occur at any stage of testing</td>
    </tr>
    <tr>
      <td><font color="blue">Acceptable </font>results in early     testing  or  trials  might  not be repeated later</td>
    </tr>
    <tr>
      <td>Not all products in     pre<font color="blue">clinical testing</font> or early stage <font color="blue">clinical trials</font> will become approved     products</td>
    </tr>
    <tr>
      <td>Before we can <font color="blue">file <font color="blue">application</font>s with</font> the FDA for product approval,     we must show that a particular product candidate is safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Even     </font><font color="blue">with respect</font> to those product <font color="blue">candidates</font> currently in <font color="blue">clinical trials</font>, we     <font color="blue">must demonstrate</font> the safety and efficacy of those product <font color="blue">candidates</font> before     we can secure FDA approval</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">adequately show</font> the safety and     <font color="blue">effective</font>ness of our product <font color="blue">candidates</font> would prevent FDA approval of our     products</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> costs will increase if we experience     delays in testing or <font color="blue"><font color="blue">regulatory</font> approval</font>s or if we need to perform more or     larger <font color="blue">clinical trials</font> than planned</td>
    </tr>
    <tr>
      <td>If the delays are <font color="blue">significant</font>, they     <font color="blue"><font color="blue">could <font color="blue">negatively</font></font> affect</font> our financial results and the <font color="blue">commercial prospects</font>     for our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Because we or our <font color="blue">collaborators</font> must obtain <font color="blue"><font color="blue">regulatory</font> approval</font> to market     our products in the <font color="blue">United States</font> and in non-US <font color="blue">jurisdictions</font>, we cannot     <font color="blue">predict whether</font> or when we will be permitted to <font color="blue">commercialize</font> our products;     failure to <font color="blue"><font color="blue">comply with</font> applicable <font color="blue">regulations</font></font> can also harm our business and     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>•   The <font color="blue">pharmaceutical</font> industry is subject to <font color="blue">stringent regulation by</font> a     wide range of <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>We cannot <font color="blue">predict whether</font> we or our <font color="blue">collaborators</font>     will obtain <font color="blue"><font color="blue">regulatory</font> approval</font> for any product we develop</td>
    </tr>
    <tr>
      <td>No one can     market a <font color="blue">pharmaceutical</font> product in the <font color="blue">United States</font> until it has completed     rigorous pre<font color="blue">clinical testing</font> and <font color="blue">clinical trials</font> of the product and an     extensive <font color="blue"><font color="blue">regulatory</font> approval</font> process implemented by the FDA To date, the     FDA has not approved a <font color="blue"><font color="blue">gene therapy</font> product</font> for sale in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td><font color="blue">Satisfaction </font>of <font color="blue">regulatory</font> <font color="blue">requirements</font> typically takes many years, is     <font color="blue">dependent</font> upon the type, <font color="blue">complexity</font> and novelty of the product and requires     the <font color="blue">expenditure</font> of substantial resources</td>
    </tr>
    <tr>
      <td>Of <font color="blue">particular significance</font> are the     <font color="blue">requirements</font> covering research and <font color="blue">development</font>, testing, <font color="blue">manufacturing</font>,     <font color="blue">quality control</font>, labeling and promotion of drugs for human use</td>
    </tr>
    <tr>
      <td><font color="blue">Before     </font>commencing <font color="blue">clinical trials</font>, we must submit to the FDA and receive approval     from <font color="blue">the FDA of an <font color="blue">Investigational New Drug </font></font><font color="blue">application</font> (“IND”)</td>
    </tr>
    <tr>
      <td><font color="blue">Clinical     </font>trials are subject to oversight by Institutional Review Boards and the FDA     Clinical trials are also subject to:         •   <font color="blue">informed consent</font>;         •   good <font color="blue">clinical practices</font> (GCP);         •   continuing FDA oversight;         •   <font color="blue">potentially</font> large numbers of <font color="blue">test subjects</font>; and         •   <font color="blue">potential suspension by us</font>, our <font color="blue">collaborators</font> or the FDA at any time     if it is believed that the <font color="blue">subjects participating</font> in these trials are being     exposed to unacceptable <font color="blue">health risks</font> or if the FDA <font color="blue">finds deficiencies</font> in the     <font color="blue">Investigational New Drug </font><font color="blue">application</font> or the conduct of these trials</td>
    </tr>
    <tr>
      <td>We <font color="blue">may encounter delays</font> or <font color="blue">rejections</font> in the <font color="blue"><font color="blue">regulatory</font> approval</font> process     because of <font color="blue">additional</font> <font color="blue">government</font> regulation from future legislation or     <font color="blue">administrative action</font> or changes in FDA <font color="blue">policy during</font> the period of product     <font color="blue">development</font>, <font color="blue">clinical trials</font> and FDA <font color="blue">regulatory</font> review</td>
    </tr>
    <tr>
      <td>Failure to comply     with applicable FDA or other applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> may result     in criminal prosecution, civil penalties, recall or seizure of products,     total or <font color="blue">partial suspension</font> of production or injunction, as well as other     <font color="blue">regulatory</font>  <font color="blue">action against</font> our product <font color="blue">candidates</font> or us</td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font>     approval of a product is granted, this <font color="blue">approval will</font> be limited to those     <font color="blue">disease <font color="blue">indications</font></font> for which the product has shown through <font color="blue">clinical trials</font>     to be safe and <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>The FDA <font color="blue">also strictly regulates promotion</font> and     labeling after approval</td>
    </tr>
    <tr>
      <td>Outside the <font color="blue">United States</font>, our ability to market a     product  is  <font color="blue">contingent upon</font> receiving <font color="blue">clearances from</font> the <font color="blue">appropriate</font>     <font color="blue"><font color="blue">regulatory</font> <font color="blue">authorities</font></font></td>
    </tr>
    <tr>
      <td>This non-US <font color="blue"><font color="blue">regulatory</font> approval</font> process includes     risks similar to those <font color="blue">associated with</font> FDA <font color="blue">clearance described</font> above</td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________           If  we  or our <font color="blue">collaborators</font> are unable to <font color="blue">manufacture</font> our products in     <font color="blue">sufficient quantities</font> or are unable to obtain <font color="blue"><font color="blue">regulatory</font> approval</font>s for a     <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> for our products, we may experience delays, and be     unable to meet demand, and <font color="blue">may lose potential revenues</font></td>
    </tr>
    <tr>
      <td><font color="blue">Completion </font>of our <font color="blue">clinical trials</font> and <font color="blue">commercialization</font> of our product     <font color="blue">candidates</font> require access to, or <font color="blue">development</font> of, <font color="blue">facilities</font> to <font color="blue">manufacture</font> a     <font color="blue">sufficient supply</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We have limited experience     <font color="blue">manufacturing</font> any of our gene-based products in the volumes that will be     <font color="blue">necessary</font> to support large-scale <font color="blue">clinical trials</font> or <font color="blue">commercial sales</font></td>
    </tr>
    <tr>
      <td>We do     not yet know the extent to which we will be able to develop our <font color="blue">Gaithersburg     </font><font color="blue">manufacturing</font> <font color="blue">facilities</font> and processes to the <font color="blue">manufacture</font> of <font color="blue">gene therapy</font>     product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Efforts to establish <font color="blue">capabilities</font>, if pursued, may not     meet initial <font color="blue">expectations</font> as to scheduling, <font color="blue">reproducibility</font>, yield, purity,     cost, potency or quality</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">collaborators</font> are unable to <font color="blue">manufacture</font> our product <font color="blue">candidates</font>     in clinical quantities or, when <font color="blue">necessary</font>, commercial quantities, then we     will need to rely on <font color="blue">third parties</font> to <font color="blue">manufacture</font> compounds for clinical and     commercial  purposes</td>
    </tr>
    <tr>
      <td>These third-party <font color="blue">manufacture</font>rs must receive FDA     approval before they can produce clinical material or <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td>Our products may be in <font color="blue"><font color="blue">competition</font> with</font> other products for access to these     <font color="blue">facilities</font> and may be subject to delays in <font color="blue">manufacture</font> if <font color="blue">third parties</font> give     other <font color="blue">products greater priority</font></td>
    </tr>
    <tr>
      <td>In addition, we may not be able to enter     into any <font color="blue">necessary</font> third-party <font color="blue">manufacturing</font> <font color="blue">arrangements</font> on acceptable     terms, or on a <font color="blue">timely basis</font></td>
    </tr>
    <tr>
      <td>There are very few contract <font color="blue">manufacture</font>rs who     currently have the <font color="blue">capability</font> to produce our <font color="blue">proposed products</font>, and the     <font color="blue">inability</font> of any of these contract <font color="blue">manufacture</font>rs to deliver our required     quantities of product <font color="blue">candidates</font> on a <font color="blue">timely basis</font> and <font color="blue">at commercially</font>     reasonable prices would <font color="blue">negatively</font> affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Before we or our <font color="blue">collaborators</font> can begin commercial <font color="blue">manufacturing</font> of any of     our product <font color="blue">candidates</font>, we or our <font color="blue">collaborators</font> must obtain <font color="blue">regulatory</font>     approval of the <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> and process</td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturing </font>of our     <font color="blue">proposed products</font> must <font color="blue">comply with</font> the FDA’s current Good <font color="blue">Manufacturing </font>    Practices <font color="blue">requirements</font>, commonly known as cGMP, and non-US <font color="blue">regulatory</font>     <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>The cGMP <font color="blue">requirements</font> govern <font color="blue">quality control</font> and <font color="blue">documentation</font>     policies and procedures</td>
    </tr>
    <tr>
      <td>In <font color="blue">complying with cGMP</font> and non-US <font color="blue">regulatory</font>     <font color="blue">requirements</font>, we will be obligated to expend time, money and effort in     production, record keeping and <font color="blue">quality control</font> to assure that the product     meets  applicable  <font color="blue">specifications</font>  and  other  <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>We or our     <font color="blue">collaborators</font> must also pass a pre-approval inspection before FDA approval</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">collaborators</font> fail to <font color="blue">comply with</font> these <font color="blue">requirements</font>, our     product <font color="blue">candidates</font> would not be approved</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">collaborators</font> fail to     comply  with these <font color="blue">requirements</font> after approval, we would be subject to     possible <font color="blue">regulatory</font> action and may be limited in the <font color="blue">jurisdictions</font> in which     we are permitted to sell our products</td>
    </tr>
    <tr>
      <td>The FDA and non-US <font color="blue">regulatory</font>     <font color="blue">authorities</font>  also  have  the authority to perform unannounced periodic     <font color="blue">inspections</font> of our <font color="blue"><font color="blue">manufacturing</font> <font color="blue">facility</font></font> to ensure <font color="blue">compliance with</font> cGMP and     non-US <font color="blue">regulatory</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>If successful large-scale <font color="blue">manufacturing</font> of gene-based medicines is not     possible, we may be unable to <font color="blue">manufacture</font> enough of our product <font color="blue">candidates</font>     to achieve <font color="blue"><font color="blue">regulatory</font> approval</font> or market our products</td>
    </tr>
    <tr>
      <td>Very  <font color="blue">few companies</font> have shown successful large-scale <font color="blue">manufacturing</font> of     gene-based medicines, and there are <font color="blue">significant</font> uncertainties and risks     <font color="blue">associated with</font> the scale up of our <font color="blue">manufacturing</font> processes to commercial     levels</td>
    </tr>
    <tr>
      <td>There are a limited number of contract <font color="blue">manufacture</font>rs qualified to     perform large-scale <font color="blue">manufacturing</font> of gene-based medicines</td>
    </tr>
    <tr>
      <td>We may be unable     to  <font color="blue">manufacture</font> commercial-scale quantities of gene-base medicines, or     receive <font color="blue">appropriate</font> <font color="blue">government</font> approvals, on a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Failure  </font>to  <font color="blue">successfully</font> <font color="blue">manufacture</font> or obtain <font color="blue">appropriate</font> <font color="blue">government</font>     approvals on a <font color="blue">timely basis</font> or at all would prevent us from achieving our     business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">difficult</font>ies or delays in product <font color="blue">manufacturing</font>, which are     beyond  our  control  and  <font color="blue">could harm</font> our business, because we rely on     third-party <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>We currently expect to produce our product <font color="blue">candidates</font> through third-party     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Problems with any <font color="blue">manufacturing</font> processes could result in     product defects, which could require us to <font color="blue">delay shipment</font> of products or     <font color="blue">recall products previously shipped</font></td>
    </tr>
    <tr>
      <td>In addition, any <font color="blue">prolonged <font color="blue">interruption</font></font>     in the <font color="blue">operations</font> of our or a third party’s <font color="blue">manufacturing</font> <font color="blue">facilities</font> could     result in the <font color="blue">cancellation</font> of shipments</td>
    </tr>
    <tr>
      <td>A number of <font color="blue">factors could</font> cause     <font color="blue"><font color="blue">interruption</font>s</font>, including <font color="blue">equipment malfunctions</font> or <font color="blue">process failures</font>, or     damage to a <font color="blue">facility</font> due to <font color="blue">natural disasters</font> or otherwise</td>
    </tr>
    <tr>
      <td>Because our     <font color="blue">manufacturing</font> processes are or are expected to be <font color="blue">highly complex</font> and subject     to a lengthy FDA approval process, alternative qualified production capacity     may not be <font color="blue">available on</font> a <font color="blue">timely basis</font> or at all</td>
    </tr>
    <tr>
      <td><font color="blue">Difficulties </font>or delays in our <font color="blue">manufacturing</font> could increase our costs and     damage our reputation</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of <font color="blue">pharmaceutical</font> products can be an     expensive,  time-consuming,  and  <font color="blue">complex process</font></td>
    </tr>
    <tr>
      <td><font color="blue">Manufacturers </font>often     encounter <font color="blue">difficult</font>ies in scaling-up production of <font color="blue">new products</font>, including     <font color="blue">problems involving</font> the transfer of <font color="blue">manufacturing</font> <font color="blue">technology</font>, production     yields, <font color="blue">quality control</font> and assurance, and shortages of personnel</td>
    </tr>
    <tr>
      <td>Delays in     scale-up to commercial quantities could result in <font color="blue">additional</font> expense and     delays in our <font color="blue">clinical trials</font>, <font color="blue">regulatory</font> <font color="blue">submissions</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________           We rely on a limited number of suppliers for some of our <font color="blue">manufacturing</font>     materials</td>
    </tr>
    <tr>
      <td>Any  problems  experienced by any of these <font color="blue">suppliers could</font>     <font color="blue">negatively</font> affect our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We rely on third-party suppliers and vendors for some of the <font color="blue">materials used</font>     in the <font color="blue">manufacture</font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>For supply of <font color="blue">early clinical</font>     <font color="blue">trial materials</font>, we <font color="blue">rely on one supplier</font>, Invitrogen Corporation, for its     <font color="blue">cell culture medium</font> <font color="blue">and Cambrex </font>for custom buffers</td>
    </tr>
    <tr>
      <td>The <font color="blue">cell culture medium</font>     is used to grow the <font color="blue">cells with</font>in which our product <font color="blue">candidates</font> are produced</td>
    </tr>
    <tr>
      <td>For supply of late-stage clinical <font color="blue">trial materials</font>, we currently are planning     to <font color="blue">use purification resins from</font> the Applied Biosystems Group of Applera     Corporation and the BioSepra SA Process Division of Pall Corporation</td>
    </tr>
    <tr>
      <td>We     do not currently have supply <font color="blue">agreements</font> with any of these suppliers</td>
    </tr>
    <tr>
      <td>Any     <font color="blue">significant</font> problem experienced by one of our <font color="blue">suppliers could</font> result in a     delay or <font color="blue">interruption</font> in the supply of materials to <font color="blue">us until such supplier</font>     resolves the problem or an <font color="blue">alternative source</font> of supply is located</td>
    </tr>
    <tr>
      <td>We have     limited experience with <font color="blue">alternative source</font>s of <font color="blue">raw materials</font></td>
    </tr>
    <tr>
      <td>Any delay or     <font color="blue">interruption</font> would likely lead to a delay or <font color="blue">interruption</font> of <font color="blue">manufacturing</font>     <font color="blue">operations</font>, which <font color="blue"><font color="blue">could <font color="blue">negatively</font></font> affect</font> our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We have limited marketing <font color="blue">capabilities</font>, and if we are unable to <font color="blue">enter into</font>     <font color="blue">collaborations</font>  with  marketing  partners or develop our own sales and     marketing  <font color="blue">capability</font>, we may not be successful in <font color="blue">commercializing</font> our     products</td>
    </tr>
    <tr>
      <td>We currently have limited sales, marketing and <font color="blue">distribution</font> <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>As     a result, we will depend <font color="blue">on <font color="blue">collaborations</font> with</font> <font color="blue">third parties</font> that have     established <font color="blue">distribution</font> systems and direct sales forces</td>
    </tr>
    <tr>
      <td>To the extent that     we <font color="blue">enter into</font> co-promotion or other licensing <font color="blue">arrangements</font>, our revenues     <font color="blue">will depend upon</font> the efforts of <font color="blue">third parties</font>, over which we may have little     or no control</td>
    </tr>
    <tr>
      <td>If we are unable to reach and maintain <font color="blue">agreements</font> with one or     more <font color="blue">pharmaceutical</font> companies or <font color="blue">collaborators</font>, we may be required to market     our  products  directly</td>
    </tr>
    <tr>
      <td>In any case we may elect to establish our own     specialized sales force and marketing <font color="blue">organization</font> to market our products to     physicians</td>
    </tr>
    <tr>
      <td>In order to do this, we would have to develop a marketing and     sales  <font color="blue">force with technical expertise</font> and with supporting <font color="blue">distribution</font>     <font color="blue">capability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Developing </font>a marketing and sales force is expensive and time     consuming and <font color="blue">could delay</font> a product launch</td>
    </tr>
    <tr>
      <td>We cannot be certain that we     will be able to attract and retain <font color="blue">qualified sales personnel</font> or otherwise     develop this <font color="blue">capability</font></td>
    </tr>
    <tr>
      <td>We  face  substantial  <font color="blue">competition</font>  from  other companies and research     <font color="blue"><font color="blue">institution</font>s</font> that are developing products to treat the <font color="blue">same diseases</font> that     our  product  candidate’s  target,  and  we may not be able to compete     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">compete with</font> <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies that are pursuing     other  forms of treatment for the diseases that our product <font color="blue">candidates</font>     target</td>
    </tr>
    <tr>
      <td>We  may also face <font color="blue">competition</font> from companies that may develop     competing <font color="blue">technology</font> internally or acquire it <font color="blue">from <font color="blue">universities</font></font> and other     research <font color="blue"><font color="blue">institution</font>s</font></td>
    </tr>
    <tr>
      <td>As these companies develop their <font color="blue">technologies</font>, they     may develop proprietary positions, which <font color="blue">may prevent</font> or limit our product     <font color="blue">commercialization</font> efforts</td>
    </tr>
    <tr>
      <td>Some of our <font color="blue"><font color="blue">competitor</font>s</font> are established companies with greater financial and     other resources than we have</td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">competition</font> in our business     <font color="blue">will intensify</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> may succeed in:       •   identifying <font color="blue">important genes</font> or <font color="blue">delivery mechanisms</font> before us;         •   developing products or product <font color="blue">candidates</font> earlier than we do;         •   forming <font color="blue">collaborations</font> before we do, or <font color="blue">precluding us from forming</font>     <font color="blue">collaborations</font> <font color="blue">with others</font>;         •   obtaining <font color="blue">approvals from</font> the FDA or other <font color="blue">regulatory</font> agencies for such     products more <font color="blue">rapidly than</font> we do;         •   developing and validating <font color="blue">manufacturing</font> processes more <font color="blue">rapidly than</font> we     do;         •   obtaining <font color="blue">patent protection</font> to other <font color="blue"><font color="blue">intellectual</font> property</font> rights that     <font color="blue">would limit</font> or preclude our ability to use our <font color="blue">technologies</font> or develop     products; or         •   developing products that are safer or more <font color="blue">effective</font> than those we     develop or propose to develop</td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________           While  we  seek  to  expand  our  technological <font color="blue">capabilities</font> to remain     <font color="blue">competitive</font>, research and <font color="blue">development</font> by others may render our <font color="blue">technology</font> or     product <font color="blue">candidates</font> obsolete or non<font color="blue">competitive</font> or result in <font color="blue">treatments</font> or     cures superior to any therapy developed by us</td>
    </tr>
    <tr>
      <td>RISKS RELATED TO OUR INDUSTRY     If we are unable to <font color="blue">adequately protect</font> our <font color="blue"><font color="blue">intellectual</font> property</font> rights, our     <font color="blue"><font color="blue">competitor</font>s</font> may be able to take advantage of our research and <font color="blue">development</font>     efforts to <font color="blue"><font color="blue">compete with</font> us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">commercial success</font> will depend</font> in part on obtaining <font color="blue">patent protection</font>     for our products and other <font color="blue">technologies</font> and <font color="blue">successfully</font> defending these     <font color="blue">patents against third party challenges</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">patent position</font>, like that of     other bio<font color="blue">technology</font> firms, is <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font>     and factual questions</td>
    </tr>
    <tr>
      <td>The bio<font color="blue">technology</font> patent situation in the United     States and other countries is uncertain and is <font color="blue">currently undergoing review</font>     and revision</td>
    </tr>
    <tr>
      <td>Changes in, or <font color="blue">different</font> interpretations of, <font color="blue">patent laws</font> in     the  United  States  and other <font color="blue">countries might allow others</font> to use our     <font color="blue">discoveries</font>  or  to develop and <font color="blue">commercialize</font> our <font color="blue">products without</font> any     <font color="blue">compensation</font> to us</td>
    </tr>
    <tr>
      <td>Our  ability  to  develop  and protect a proprietary position <font color="blue">based on</font>     <font color="blue">biotechnological innovations</font> and <font color="blue">technologies</font> involving genes and gene     therapy,  delivery  systems, production, formulations and the like, is     <font color="blue">particularly uncertain</font></td>
    </tr>
    <tr>
      <td>The US Patent and Trademark Office, as well as the     patent  offices  in  other  countries, have often required that patent     <font color="blue">application</font>s concerning bio<font color="blue">technology</font>-related <font color="blue">inventions</font> be limited or     narrowed <font color="blue">substantially</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">disclosure</font>s</font> in our patent <font color="blue">application</font>s may not     be sufficient to meet the statutory <font color="blue">requirements</font> for <font color="blue">patentability</font> in all     cases</td>
    </tr>
    <tr>
      <td>In addition, other companies or <font color="blue"><font color="blue">institution</font>s</font> possess <font color="blue">issued patents</font>     and have filed and will file patent <font color="blue">application</font>s that cover or attempt to     cover genes, vectors, cell lines, and methods of making and using gene     <font color="blue">therapy products</font> that are the same as or similar to the subject matter of     our  patent  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>For  example, while we have <font color="blue">pending patent</font>     <font color="blue">application</font>s pertaining to particular <font color="blue">adenovectors</font> that <font color="blue">cannot reproduce</font>     themselves, and <font color="blue">adenovectors</font> modified to alter cell binding <font color="blue">characteristics</font>,     we are aware of <font color="blue">issued patents</font> and <font color="blue">pending patent</font> <font color="blue">application</font>s of other     companies and <font color="blue"><font color="blue">institution</font>s</font> relating to the same subject matter</td>
    </tr>
    <tr>
      <td>Patents and     patent <font color="blue">application</font>s of <font color="blue">third parties</font> may have priority over our issued     patents and our pending or yet to be filed patent <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Proceedings     </font>before the <font color="blue">US Patent and Trademark Office </font>and other <font color="blue">patent offices</font> to     determine  who  properly  lays claim to <font color="blue">inventions</font> are costly and time     consuming, and we may not win in any <font color="blue">such proceedings</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">issued patents</font> we already have or may obtain in the <font color="blue">future may</font> not     provide  commercially meaningful protection against <font color="blue"><font color="blue">competitor</font>s</font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font>companies or <font color="blue"><font color="blue">institution</font>s</font> may challenge our or our <font color="blue">collaborators</font>’ patents in     the <font color="blue">United States</font> and other countries</td>
    </tr>
    <tr>
      <td>In the event a company, <font color="blue">institution</font>     or  researcher infringes upon our or our <font color="blue">collaborators</font>’ patent rights,     enforcing  these <font color="blue">rights may</font> be <font color="blue">difficult</font> and can be expensive and time     consuming, with no guarantee that our or our <font color="blue">collaborators</font>’ patent rights     will be upheld</td>
    </tr>
    <tr>
      <td>Others may be able to <font color="blue">design around</font> these patents or develop     <font color="blue">unique products providing effects</font> similar to our products</td>
    </tr>
    <tr>
      <td>In addition, our     <font color="blue"><font color="blue">competitor</font>s</font> may legally challenge our patents and they may be held to be     invalid</td>
    </tr>
    <tr>
      <td>In addition, various <font color="blue">components</font> used in developing <font color="blue">gene therapy</font>     products, such as particular genes, vectors, promoters, cell lines and     construction methods, used by others and us, are available to the public</td>
    </tr>
    <tr>
      <td>As     a result, we are unable to obtain <font color="blue">patent protection</font> <font color="blue">with respect</font> to such     <font color="blue">components</font>, and <font color="blue">third parties</font> can freely use such <font color="blue">components</font></td>
    </tr>
    <tr>
      <td>Third parties     may develop products using such <font color="blue">components</font> that <font color="blue">compete with</font> our potential     products</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">with respect</font> to some of our patentable <font color="blue">inventions</font>, we or our     <font color="blue">collaborators</font> have decided not to pursue <font color="blue">patent protection</font> outside the     <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue"><font color="blue">competitor</font>s</font> could develop, and receive     non-US <font color="blue">patent protection</font> for, <font color="blue">gene therapies</font> or <font color="blue">technologies</font> for which we     or  our  <font color="blue">collaborators</font> have or are seeking US <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>Our     <font color="blue"><font color="blue">competitor</font>s</font> may be free to use these <font color="blue">gene therapies</font> or <font color="blue">technologies</font> outside     the <font color="blue">United States</font> in the absence of <font color="blue">patent protection</font></td>
    </tr>
    <tr>
      <td>Where we believe <font color="blue">patent protection</font> is not <font color="blue">appropriate</font> we rely to a limited     <font color="blue">extent on <font color="blue">trade secrets</font></font> to protect our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>However, <font color="blue">trade secrets</font>     are  <font color="blue">difficult</font>  to protect</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">entered into confidentiality</font>     <font color="blue">agreements</font> with employees and <font color="blue">collaborators</font>, we may not be able to prevent     the <font color="blue">disclosure</font> or use of our <font color="blue">trade secrets</font></td>
    </tr>
    <tr>
      <td>In addition, other companies or     <font color="blue"><font color="blue">institution</font>s</font> may in<font color="blue">dependent</font>ly develop <font color="blue">substantially</font> equivalent information     and <font color="blue">techniques</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________           If our <font color="blue">potential products</font> <font color="blue">conflict with</font> <font color="blue"><font color="blue">intellectual</font> property</font> rights of     <font color="blue"><font color="blue">competitor</font>s</font>,  <font color="blue">universities</font>  or  others,  then we may be <font color="blue">prevented from</font>     developing those product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Other companies and <font color="blue"><font color="blue">institution</font>s</font> have <font color="blue">issued patents</font> and have filed and will     file patent <font color="blue">application</font>s that <font color="blue">may issue into patents</font> that cover or attempt     to cover genes, vectors, cell lines and methods of making and using gene and     gene-based <font color="blue">therapy products</font> used in or similar to our product <font color="blue">candidates</font> and     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>For example, we are aware of <font color="blue">issued patents</font> and <font color="blue">pending patent</font>     <font color="blue">application</font>s  relating  to  the delivery, including through the use of     <font color="blue">adenovectors</font>, of <font color="blue">medically beneficial substances</font> to the heart and other     tissues</td>
    </tr>
    <tr>
      <td>We also are aware of other <font color="blue">issued patents</font> and <font color="blue">pending patent</font>     <font color="blue">application</font>s that relate to <font color="blue">various aspects</font> of our other product <font color="blue">candidates</font>     and systems, including TNFerade, and it could be alleged that our product     <font color="blue">candidates</font> <font color="blue">conflict with</font> these patents</td>
    </tr>
    <tr>
      <td>We have not <font color="blue">conducted freedom</font> to use     patent  <font color="blue">searches on</font> all aspects of our product <font color="blue">candidates</font> or potential     product <font color="blue">candidates</font>, and we may be unaware of <font color="blue">relevant patents</font> and patent     <font color="blue">application</font>s of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>In addition, those freedom to use patent     searches that have been conducted may not have identified all relevant     <font color="blue">issued patents</font> or all relevant <font color="blue">pending patent</font> <font color="blue">application</font>s that <font color="blue">could issue</font>     into patents, particularly in view of the <font color="blue">characterizations</font> of the subject     matter of <font color="blue">issued patents</font> and <font color="blue">pending patent</font> <font color="blue">application</font>s, as well as the     fact that <font color="blue">pending patent</font> <font color="blue">application</font>s can be maintained in secrecy for a     period of time and, in some <font color="blue">circumstances</font>, until issuance as patents</td>
    </tr>
    <tr>
      <td>An <font color="blue">issued patent gives rise</font> to a <font color="blue">rebuttable presumption</font> of <font color="blue">validity under</font>     US law and the laws of some other countries</td>
    </tr>
    <tr>
      <td>The holder of a patent to     which  we or our <font color="blue">collaborators</font> do not hold a <font color="blue">license could bring legal</font>     <font color="blue">actions against</font> our <font color="blue">collaborators</font> or us for damages or to stop us or our     <font color="blue">collaborators</font> from using the affected <font color="blue">technology</font>, which could limit or     preclude our ability to develop and <font color="blue">commercialize</font> our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If     any of our <font color="blue">potential products</font> are found to infringe a patent of a <font color="blue">competitor</font>     or third party, we or our <font color="blue">collaborators</font> may be required to pay damages and     to either obtain a license in order to continue to develop and <font color="blue">commercialize</font>     the <font color="blue">potential products</font> or, at the <font color="blue">discretion</font> of the <font color="blue">competitor</font> or third     party, to stop <font color="blue">development</font> and <font color="blue">commercialization</font> of the <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Since we have <font color="blue">concentrated</font> our <font color="blue">resources on</font> developing only a limited number     of  products,  the  <font color="blue">inability</font>  to  market  one  of  our <font color="blue">products would</font>     <font color="blue">disproportionately affect us as opposed</font> to a <font color="blue">competing company with</font> many     products in <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We  believe  that <font color="blue">there will</font> be <font color="blue">significant</font> <font color="blue">litigation</font> in our industry     regarding  <font color="blue">intellectual</font>  <font color="blue">property rights</font></td>
    </tr>
    <tr>
      <td>Many of our <font color="blue"><font color="blue">competitor</font>s</font> have     expended and are continuing to expend <font color="blue">significant</font> amounts of time, money and     <font color="blue">management</font> <font color="blue">resources on</font> <font color="blue"><font color="blue">intellectual</font> property</font> <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>If we become     involved  in <font color="blue">litigation</font>, it <font color="blue">could consume</font> a substantial portion of our     resources and could <font color="blue">adversely</font> affect our business, <font color="blue">financial condition</font> and     results  of  <font color="blue">operations</font>,  even if we ultimately are successful in such     <font color="blue">litigation</font>, in view of our limited resources</td>
    </tr>
    <tr>
      <td>If  our  right  to use <font color="blue"><font color="blue">intellectual</font> property</font> we <font color="blue">license from others</font> is     affected, our ability to develop and <font color="blue">commercialize</font> our product <font color="blue">candidates</font>     may be harmed</td>
    </tr>
    <tr>
      <td>We rely, in part, on licenses to use some <font color="blue">technologies</font> that are material to     our business</td>
    </tr>
    <tr>
      <td>For example, to create our product <font color="blue">candidates</font>, we combine our     <font color="blue">vectors with genes intended</font> to produce proteins</td>
    </tr>
    <tr>
      <td>For our <font color="blue">current product</font>     <font color="blue">candidates</font>, we have <font color="blue">secured licenses</font> to use the VEGF[121], TNF — alpha, and     PEDF genes</td>
    </tr>
    <tr>
      <td>We do not own the patents or patent <font color="blue">application</font>s that underlie     these licenses</td>
    </tr>
    <tr>
      <td>For these genes, we do not control the <font color="blue">enforcement</font> of the     patents</td>
    </tr>
    <tr>
      <td>We rely upon our <font color="blue">licensors</font> to <font color="blue">properly prosecute</font> and file those     patent <font color="blue">application</font>s and to <font color="blue">prevent infringement</font> of those patents</td>
    </tr>
    <tr>
      <td>While  many of the <font color="blue">licenses under which</font> we have <font color="blue">rights provide us with</font>     <font color="blue">exclusive rights</font> in <font color="blue">specified fields</font>, the scope of our <font color="blue">rights under</font> these     and other <font color="blue">licenses may</font> be subject to <font color="blue">dispute by</font> our <font color="blue">licensors</font> or third     parties</td>
    </tr>
    <tr>
      <td>In addition, our rights to use these <font color="blue">technologies</font> and practice the     <font color="blue">inventions</font> claimed in the <font color="blue">licensed patents</font> and patent <font color="blue">application</font>s are     subject to our <font color="blue">licensors</font> abiding by the terms of those licenses and not     <font color="blue">terminating them</font></td>
    </tr>
    <tr>
      <td>Any of our <font color="blue">licenses may</font> be terminated by the licensor if     we are in breach of a term or condition of the <font color="blue">license agreement</font>, or in     certain other <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>In addition, some of our licenses require us to     achieve <font color="blue">specific milestones</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> and potential product <font color="blue">candidates</font> will require several     <font color="blue">components</font>  that  may  each be the subject of a <font color="blue">license agreement</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">cumulative license fees</font> and royalties for these <font color="blue">components</font> may make the     <font color="blue">commercialization</font> of these product <font color="blue">candidates</font> uneconomical</td>
    </tr>
    <tr>
      <td>21       _________________________________________________________________           Adverse events in the field of <font color="blue">gene therapy</font> may <font color="blue">negatively</font> affect <font color="blue">regulatory</font>     approval or <font color="blue">public <font color="blue">perception</font></font> of our products or product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td><font color="blue">In September </font>1999, a patient undergoing <font color="blue">gene therapy</font> using an <font color="blue">adenoviral</font>     vector to deliver a <font color="blue">therapeutic gene died as</font> a result of an <font color="blue">adverse reaction</font>     to the treatment</td>
    </tr>
    <tr>
      <td>This death was <font color="blue">widely publicized</font></td>
    </tr>
    <tr>
      <td>Other <font color="blue">patient deaths</font>     have occurred in other gene-based <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>These deaths and the     resulting publicity surrounding them, as well as any other <font color="blue">serious adverse</font>     events in the field of <font color="blue">gene therapy</font> that may occur in the future, may result     in greater <font color="blue">government</font>al regulation of our product <font color="blue">candidates</font> and potential     <font color="blue">regulatory</font>  delays  relating to the testing or approval of our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>As a result of the incident in September 1999, the <font color="blue">United States</font>     Senate held a series of hearings to determine whether <font color="blue">additional</font> legislation     was  required  to <font color="blue">protect patients</font> who <font color="blue">participate</font> in <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue">extended patient</font>     follow-up  for  gene  therapy product <font color="blue">candidates</font> has <font color="blue">been recommended</font></td>
    </tr>
    <tr>
      <td>Additionally, the National Institutes of Health and its advisory bodies     routinely review the field of <font color="blue">gene therapy</font> and issue reports on the adverse     events  reported  by <font color="blue">investigators</font></td>
    </tr>
    <tr>
      <td>The NIH has approved a proposal to     establish a <font color="blue">Gene Transfer Safety Assessment Board </font>to review <font color="blue">serious adverse</font>     event reports, annual reports and other safety information in order to     <font color="blue">assess toxicity</font> and safety and report these <font color="blue">findings at</font> NIH Recombinant DNA     Advisory Committee (RAC) meetings</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">scrutiny cannot</font> be ruled out</td>
    </tr>
    <tr>
      <td>Any increased scrutiny <font color="blue">could delay</font> or increase the costs of our product     <font color="blue">development</font> efforts or <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercial success</font> of our product <font color="blue">candidates</font> will depend in part on     public  <font color="blue">acceptance</font>  of the use of <font color="blue">gene therapies</font> for the prevention or     treatment of <font color="blue">human disease</font></td>
    </tr>
    <tr>
      <td>Public <font color="blue">attitudes may</font> be <font color="blue">influenced by</font> claims     that <font color="blue">gene therapy</font> is unsafe, and <font color="blue">gene therapy</font> may not gain the <font color="blue">acceptance</font> of     the  public or the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">public reaction</font> to gene     therapy could result in greater <font color="blue">government</font> regulation and <font color="blue">stricter clinical</font>     <font color="blue">trial oversight</font> and commercial product labeling <font color="blue">requirements</font> of <font color="blue">gene therapy</font>     products and could cause a decrease in the demand for any products we may     develop</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> involve new <font color="blue">technologies</font> and therapeutic approaches     in  the  field  of <font color="blue">gene therapy</font>, which is a new and <font color="blue">evolving field</font></td>
    </tr>
    <tr>
      <td>As     discussed above, no <font color="blue"><font color="blue">gene therapy</font> product</font> has received <font color="blue"><font color="blue">regulatory</font> approval</font> in     the <font color="blue">United States</font>, and adverse events in this field may <font color="blue">negatively</font> affect     <font color="blue">public <font color="blue">perception</font></font> of our product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Even if our product <font color="blue">candidates</font>     attain  <font color="blue">regulatory</font>  approval, our success <font color="blue">will depend upon</font> the medical     community, patients and third party payors accepting <font color="blue"><font color="blue">gene therapy</font> product</font>s     in general, and our product <font color="blue">candidates</font> in particular, as medically useful,     cost-<font color="blue">effective</font>  and  safe</td>
    </tr>
    <tr>
      <td>In particular, our success <font color="blue">will depend upon</font>     <font color="blue">physicians specializing</font> in the treatment of those diseases that our product     <font color="blue">candidates</font> target prescribing <font color="blue">treatments</font> that involve the use of our product     <font color="blue">candidates</font> in lieu of, or in addition to, existing <font color="blue">treatments</font> that they are     <font color="blue">already familiar with</font> and for <font color="blue">which greater clinical data may</font> be available</td>
    </tr>
    <tr>
      <td>Even  if the <font color="blue">clinical safety</font> and efficacy of our product <font color="blue">candidates</font> is     established,  <font color="blue">physicians may elect</font> not to recommend our products for a     variety of reasons, including the <font color="blue"><font color="blue">reimbursement</font> policies</font> of <font color="blue">government</font> and     third-party payors</td>
    </tr>
    <tr>
      <td>Further, third-party payors, such as health insurance     plans, may be reluctant to authorize and pay for new forms of treatment that     they may deem expensive and less-proven that existing <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>Even if     gene  therapy  products, and our product <font color="blue">candidates</font> in particular, are     <font color="blue">accepted by</font> the <font color="blue">medical community</font> and third-party payors, the public in     general, or patients in particular, may be <font color="blue">uncomfortable with new therapies</font>,     including our product <font color="blue">candidates</font>, and it could take substantial time for     them to accept <font color="blue"><font color="blue">gene therapy</font> product</font>s as a <font color="blue">viable treatment alternative</font>, if     ever</td>
    </tr>
    <tr>
      <td>If <font color="blue">gene therapy</font> and our product <font color="blue">candidates</font> do not <font color="blue">gain widespread</font>     <font color="blue">acceptance</font>, we may be unable to generate <font color="blue">significant</font> revenues, if any, which     would <font color="blue">adversely</font> affect our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, even if our     product <font color="blue">candidates</font> achieve market <font color="blue">acceptance</font>, we may not be able to maintain     that  market  <font color="blue">acceptance</font> over time if <font color="blue">new products</font> or <font color="blue">technologies</font> are     introduced that are more favorably received than our product <font color="blue">candidates</font> or     render <font color="blue">them obsolete</font></td>
    </tr>
    <tr>
      <td>We may be sued for <font color="blue">product <font color="blue">liability</font></font>, which could damage our reputation and     expose us to <font color="blue">unanticipated costs</font></td>
    </tr>
    <tr>
      <td>We, alone or with our <font color="blue">collaborators</font>, may be held liable if any product we or     our <font color="blue">collaborators</font> develop, or any product, which is made with the use or     <font color="blue">incorporation</font>  of  any  of our <font color="blue">technologies</font>, causes injury or is found     otherwise unsuitable during product testing, <font color="blue">manufacturing</font>, marketing or     sale</td>
    </tr>
    <tr>
      <td><font color="blue">Regardless </font>of the merit or eventual outcome, <font color="blue">product <font color="blue">liability</font></font> claims     may result in:       •   withdrawal of product <font color="blue">candidates</font> from our <font color="blue">clinical trials</font>;         •   withdrawal of our products from the market; if they have been     approved;         •   damage to our reputation;         •   costs of <font color="blue">litigation</font>;         •   substantial <font color="blue">monetary awards</font> to plaintiffs; and         •   <font color="blue">decreased demand</font> for our products or product <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________           <font color="blue">Although  </font>we  currently  have and intend to maintain <font color="blue">product <font color="blue">liability</font></font>     insurance, this <font color="blue">insurance may become prohibitively expensive</font>, or may not     fully  cover our <font color="blue">potential liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Inability </font>to obtain sufficient     insurance coverage at an acceptable cost or otherwise to protect against     potential  product  <font color="blue">liability</font>  claims  could  prevent  or  inhibit the     <font color="blue">commercialization</font> of products developed by us or in <font color="blue">collaboration with</font>     others</td>
    </tr>
    <tr>
      <td>Currently, we have a total of dlra5 million <font color="blue">liability</font> coverage under a     <font color="blue">clinical trials</font> and professional <font color="blue">liability</font> insurance policy</td>
    </tr>
    <tr>
      <td>If we are sued     for any injury caused by our products, our <font color="blue">liability</font> could exceed our total     resources</td>
    </tr>
    <tr>
      <td>We <font color="blue">use <font color="blue">hazardous</font> <font color="blue">chemicals</font></font> and <font color="blue">radioactive</font> and <font color="blue">biological materials</font> in our     business; any <font color="blue">liability</font> or disputes relating to improper handling, storage     or disposal of these <font color="blue">materials could</font> be time consuming and costly</td>
    </tr>
    <tr>
      <td>Our  research  and  <font color="blue">development</font> processes involve the use of <font color="blue">hazardous</font>     materials, including <font color="blue">chemicals</font> and <font color="blue">radioactive</font> and <font color="blue">biological materials</font>, and     also produce <font color="blue">hazardous</font> waste products</td>
    </tr>
    <tr>
      <td><font color="blue">Hazardous </font><font color="blue">chemicals</font> used in our     processes  include, but are not limited to, <font color="blue">flammable solvents such as</font>     methanol  and  ethanol,  toxic  <font color="blue">chemicals</font> such as ethidium bromide and     <font color="blue">formaldehyde</font>,  and  corrosive <font color="blue">chemicals</font> such as acetic acid and sodium     hydroxide</td>
    </tr>
    <tr>
      <td>We  also  use  several  <font color="blue">radioactive</font>  compounds,  including     phosphorous-32,   carbon-14,  sulfur-35,  phosphorous-33,  iodine-125,     hydrogen-3, and chromium-51</td>
    </tr>
    <tr>
      <td>The <font color="blue">hazardous</font> biological material used in our research and <font color="blue">development</font>     <font color="blue">activities</font>  include  human  and <font color="blue">animal cell lines</font> and viruses, such as     <font color="blue">adenoviruses</font>,  and  animals  infected  <font color="blue">with human viruses</font></td>
    </tr>
    <tr>
      <td>Some of the     biological material may be novel, including <font color="blue">viruses with novel properties</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot eliminate</font> the risk of <font color="blue">accidental <font color="blue">contamination</font></font> or discharge or     <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>Federal, state, and <font color="blue">local laws</font> and <font color="blue">regulations</font>     govern  the  use, <font color="blue">manufacture</font>, storage, handling and disposal of these     materials</td>
    </tr>
    <tr>
      <td>We could be subject to <font color="blue">civil damages</font> in the event of an improper     or <font color="blue">unauthorized release</font> of, or exposure of <font color="blue">individuals</font> to, these <font color="blue">hazardous</font>     materials</td>
    </tr>
    <tr>
      <td>In addition, claimants may sue us for injury or <font color="blue">contamination</font>     that results from our use or the use by <font color="blue">third parties</font> of these materials,     and our <font color="blue">liability</font> may exceed our <font color="blue">total assets</font></td>
    </tr>
    <tr>
      <td><font color="blue">Compliance </font><font color="blue">with environmental</font>     laws and <font color="blue">regulations</font> may be expensive, and current or <font color="blue">future environmental</font>     <font color="blue">regulations</font> may impair our research, <font color="blue">development</font> or <font color="blue">production efforts</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  have  general <font color="blue">liability</font> insurance, these <font color="blue">polices contain</font>     <font color="blue">exclusions</font>  from  <font color="blue">insurance against</font> claims arising <font color="blue">from pollution from</font>     chemical or <font color="blue">radioactive</font> materials</td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborators</font> are working with these     types of <font color="blue">hazardous</font> materials in <font color="blue">connection with</font> our <font color="blue">collaborations</font></td>
    </tr>
    <tr>
      <td>In the     event of a lawsuit or <font color="blue">investigation</font>, we could be held responsible for any     injury we or our <font color="blue">collaborators</font> cause to persons or <font color="blue">property by exposure</font> to,     or release of, any <font color="blue">hazardous</font> materials</td>
    </tr>
    <tr>
      <td>However, we believe that we are     currently in <font color="blue">compliance with</font> all <font color="blue">applicable environmental</font> and <font color="blue">occupational</font>     health and safety <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>If reforms in the <font color="blue">health care industry</font> make <font color="blue">reimbursement</font> for our potential     <font color="blue">products less likely</font>, the market for our <font color="blue">potential products</font> will be reduced,     and we <font color="blue">will lose potential sources</font> of revenue</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success may depend</font>, in part, on the extent to which <font color="blue">reimbursement</font> for     the costs of <font color="blue">therapeutic products</font> and related <font color="blue">treatments</font> will be available     from  third-party  payors  such  as  <font color="blue">government</font>  <font color="blue">health administration</font>     <font color="blue">authorities</font>, private health insurers, managed care programs, and other     <font color="blue">organization</font>s</td>
    </tr>
    <tr>
      <td>Over the past decade, the cost of health care has risen     <font color="blue">significant</font>ly,  and there have been numerous proposals by <font color="blue">legislators</font>,     <font color="blue">regulators</font>, and third-party health care payors to curb these costs</td>
    </tr>
    <tr>
      <td>Some of     these proposals have involved <font color="blue">limitations</font> on the amount of <font color="blue">reimbursement</font> for     <font color="blue">certain product</font>s</td>
    </tr>
    <tr>
      <td>Similar federal or state <font color="blue">health care legislation may</font> be     adopted in the future and any products that we or our <font color="blue">collaborators</font> seek to     <font color="blue">commercialize</font> may not be considered cost-<font color="blue">effective</font></td>
    </tr>
    <tr>
      <td><font color="blue">Adequate </font>third-party     insurance coverage may not be available for us to establish and maintain     <font color="blue">price levels</font> that are sufficient for <font color="blue">realization</font> of an <font color="blue">appropriate</font> return on     our <font color="blue">investment</font> in product <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Moreover, the existence or threat of     cost control measures could cause our corporate <font color="blue">collaborators</font> to be less     willing or able to pursue research and <font color="blue">development</font> programs related to our     product <font color="blue">candidates</font></td>
    </tr>
  </tbody>
</table>